Elevated levels of interleukin-2, soluble interleukin-2 receptor alpha, interleukin-6, soluble interleukin-6 receptor and vascular endothelial growth factor in serum and ascitic fluid of patients with severe ovarian hyperstimulation syndrome
Objective: To investigate the possible role of vascular endothelial growth factor, interleukin-2, soluble interleukin-2 receptor alpha, interleukin-6 and soluble interleukin-6 receptor in the pathogenesis of ovarian hyperstimulation syndrome. Study design: The study group consisted of 10 healthy wom...
Gespeichert in:
| Veröffentlicht in: | European journal of obstetrics & gynecology and reproductive biology 1999-11, Vol.87 (1), p.81-85 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 85 |
|---|---|
| container_issue | 1 |
| container_start_page | 81 |
| container_title | European journal of obstetrics & gynecology and reproductive biology |
| container_volume | 87 |
| creator | Aboulghar, M.A. Mansour, R.T. Serour, G.I. El Helw, B.A. Shaarawy, M. |
| description | Objective: To investigate the possible role of vascular endothelial growth factor, interleukin-2, soluble interleukin-2 receptor alpha, interleukin-6 and soluble interleukin-6 receptor in the pathogenesis of ovarian hyperstimulation syndrome.
Study design: The study group consisted of 10 healthy women who developed severe ovarian hyperstimulation syndrome, group A (
n=10), following ovarian stimulation by long GnRHa/hMG protocol for IVF. A control group B=10 patients underwent stimulation with the same protocol and did not develop OHSS. Blood and ascitic fluid samples were assayed for VEGF, IL-2, sIL-2Rα, IL-6 and sIL-6R by ELISA.
Results: The mean serum levels of IL-2, sIL-2Rα, IL-6, sIL-6R and VEGF in OHSS group were 297.5±190, 6588±5566, 40.6±16.6, 5280±3326 and 492±165 pg/ml as compared to 50.8±17.4, 1100±391.6, 8.5±3.5, 516±342 and 167±31.3 pg/ml in the control group, respectively,
P |
| doi_str_mv | 10.1016/S0301-2115(99)00082-2 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69321887</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0301211599000822</els_id><sourcerecordid>69321887</sourcerecordid><originalsourceid>FETCH-LOGICAL-c419t-a0a900559003a84d5e018ce4aa00e1d8d6b5cc73004540426ce487938cbe54373</originalsourceid><addsrcrecordid>eNqFkd9qFDEUxoModlt9BCUXIgodTWYmmclVkVL_QMEL9TpkkzNuNJOMSWbLPrZv0Mzuoi0I3uRAzu875-N8CD2j5A0llL_9QhpCq5pS9kqI14SQvq7qB2hF-66uOs7ah2j1BzlBpyn9KBBpGvEYnVDCOsFrukK_rxxsVQaDSwWXcBiw9Rmig_mn9VV9jlNw89rB_W8cQcOUQ8TKTRt1fq_L_y3id0Te4K1KenYqYvAm5A04qxz-HsNN3uBB6QWzHieI87jnC26z1XhwszWLz0llCz4nfGOLJBX_EXDYqmiVx5vdBDFlO5YV2YYyaOdNDCM8QY8G5RI8PdYz9O391dfLj9X15w-fLt9dV7qlIleKKEEIY-VpVN8aBoT2GlqlCAFqesPXTOuuIaRlLWlrXnp9J5per4G1TdecoZeHuVMMv2ZIWY42aXBOeQhzklw0Ne37BWQHUMeQUoRBTtGOKu4kJXLJWu6zlkuQUgi5z1rWRff8uGBej2DuqA7hFuDFESinU26Iymub_nKCC04X7OKAlfhhayHKcmjwGowteWVpgv2Pk1vVP8wY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69321887</pqid></control><display><type>article</type><title>Elevated levels of interleukin-2, soluble interleukin-2 receptor alpha, interleukin-6, soluble interleukin-6 receptor and vascular endothelial growth factor in serum and ascitic fluid of patients with severe ovarian hyperstimulation syndrome</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Aboulghar, M.A. ; Mansour, R.T. ; Serour, G.I. ; El Helw, B.A. ; Shaarawy, M.</creator><creatorcontrib>Aboulghar, M.A. ; Mansour, R.T. ; Serour, G.I. ; El Helw, B.A. ; Shaarawy, M.</creatorcontrib><description>Objective: To investigate the possible role of vascular endothelial growth factor, interleukin-2, soluble interleukin-2 receptor alpha, interleukin-6 and soluble interleukin-6 receptor in the pathogenesis of ovarian hyperstimulation syndrome.
Study design: The study group consisted of 10 healthy women who developed severe ovarian hyperstimulation syndrome, group A (
n=10), following ovarian stimulation by long GnRHa/hMG protocol for IVF. A control group B=10 patients underwent stimulation with the same protocol and did not develop OHSS. Blood and ascitic fluid samples were assayed for VEGF, IL-2, sIL-2Rα, IL-6 and sIL-6R by ELISA.
Results: The mean serum levels of IL-2, sIL-2Rα, IL-6, sIL-6R and VEGF in OHSS group were 297.5±190, 6588±5566, 40.6±16.6, 5280±3326 and 492±165 pg/ml as compared to 50.8±17.4, 1100±391.6, 8.5±3.5, 516±342 and 167±31.3 pg/ml in the control group, respectively,
P<0.001. The mean ascitic fluid IL-2, sIL-2Rα, IL-6, sIL-6R and VEGF in the OHSS group were 282.5±191.5 pg/ml, 26 020±13 995, 90.5±36, 14 900±2789 and 660±359 pg/ml as compared to 32±14.8, 1206±429.4, 12.6±1.7, 614±240 and 151±20.5 pg/ml, respectively,
P<0.001.
Conclusions: The significantly high levels of VEGF in patients with severe OHSS suggest that VEGF is a major capillary permeability agent in OHSS. Elevated levels of IL-6 in serum and peritoneal fluid support the hypothesis that IL-6 may serve as a marker of OHSS. Although serum and ascitic fluid levels of IL-2 were elevated, accumulating evidence does not support a pivotal role for IL-2 in the pathogenesis of OHSS. However, it may have a peripheral role in mediating an increase in vascular permeability. Soluble IL-2Rα and sIL-6R may be considered to be involved in OHSS. However, the patho-physiologic mechanism is the subject of further investigations. Clinical application of VEGF-receptors in the management of OHSS is awaited with interest.</description><identifier>ISSN: 0301-2115</identifier><identifier>EISSN: 1872-7654</identifier><identifier>DOI: 10.1016/S0301-2115(99)00082-2</identifier><identifier>PMID: 10579621</identifier><identifier>CODEN: EOGRAL</identifier><language>eng</language><publisher>Shannon: Elsevier Ireland Ltd</publisher><subject>Adult ; Ascitic Fluid - chemistry ; Biological and medical sciences ; Cytokines ; Endothelial Growth Factors - analysis ; Endothelial Growth Factors - blood ; Female ; Female genital diseases ; Gynecology. Andrology. Obstetrics ; Humans ; IL-2 ; IL-6 ; Interleukin-2 - analysis ; Interleukin-2 - blood ; Interleukin-6 - analysis ; Interleukin-6 - blood ; Lymphokines - analysis ; Lymphokines - blood ; Medical sciences ; Non tumoral diseases ; OHSS ; Ovarian Hyperstimulation Syndrome - blood ; Ovarian Hyperstimulation Syndrome - metabolism ; Receptors, Interleukin-2 - analysis ; Receptors, Interleukin-2 - blood ; Receptors, Interleukin-6 - analysis ; Receptors, Interleukin-6 - blood ; Reference Values ; Solubility ; Vascular Endothelial Growth Factor A ; Vascular Endothelial Growth Factors ; VEGF</subject><ispartof>European journal of obstetrics & gynecology and reproductive biology, 1999-11, Vol.87 (1), p.81-85</ispartof><rights>1999 Elsevier Science Ireland Ltd</rights><rights>1999 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c419t-a0a900559003a84d5e018ce4aa00e1d8d6b5cc73004540426ce487938cbe54373</citedby><cites>FETCH-LOGICAL-c419t-a0a900559003a84d5e018ce4aa00e1d8d6b5cc73004540426ce487938cbe54373</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/S0301-2115(99)00082-2$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1969611$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10579621$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Aboulghar, M.A.</creatorcontrib><creatorcontrib>Mansour, R.T.</creatorcontrib><creatorcontrib>Serour, G.I.</creatorcontrib><creatorcontrib>El Helw, B.A.</creatorcontrib><creatorcontrib>Shaarawy, M.</creatorcontrib><title>Elevated levels of interleukin-2, soluble interleukin-2 receptor alpha, interleukin-6, soluble interleukin-6 receptor and vascular endothelial growth factor in serum and ascitic fluid of patients with severe ovarian hyperstimulation syndrome</title><title>European journal of obstetrics & gynecology and reproductive biology</title><addtitle>Eur J Obstet Gynecol Reprod Biol</addtitle><description>Objective: To investigate the possible role of vascular endothelial growth factor, interleukin-2, soluble interleukin-2 receptor alpha, interleukin-6 and soluble interleukin-6 receptor in the pathogenesis of ovarian hyperstimulation syndrome.
Study design: The study group consisted of 10 healthy women who developed severe ovarian hyperstimulation syndrome, group A (
n=10), following ovarian stimulation by long GnRHa/hMG protocol for IVF. A control group B=10 patients underwent stimulation with the same protocol and did not develop OHSS. Blood and ascitic fluid samples were assayed for VEGF, IL-2, sIL-2Rα, IL-6 and sIL-6R by ELISA.
Results: The mean serum levels of IL-2, sIL-2Rα, IL-6, sIL-6R and VEGF in OHSS group were 297.5±190, 6588±5566, 40.6±16.6, 5280±3326 and 492±165 pg/ml as compared to 50.8±17.4, 1100±391.6, 8.5±3.5, 516±342 and 167±31.3 pg/ml in the control group, respectively,
P<0.001. The mean ascitic fluid IL-2, sIL-2Rα, IL-6, sIL-6R and VEGF in the OHSS group were 282.5±191.5 pg/ml, 26 020±13 995, 90.5±36, 14 900±2789 and 660±359 pg/ml as compared to 32±14.8, 1206±429.4, 12.6±1.7, 614±240 and 151±20.5 pg/ml, respectively,
P<0.001.
Conclusions: The significantly high levels of VEGF in patients with severe OHSS suggest that VEGF is a major capillary permeability agent in OHSS. Elevated levels of IL-6 in serum and peritoneal fluid support the hypothesis that IL-6 may serve as a marker of OHSS. Although serum and ascitic fluid levels of IL-2 were elevated, accumulating evidence does not support a pivotal role for IL-2 in the pathogenesis of OHSS. However, it may have a peripheral role in mediating an increase in vascular permeability. Soluble IL-2Rα and sIL-6R may be considered to be involved in OHSS. However, the patho-physiologic mechanism is the subject of further investigations. Clinical application of VEGF-receptors in the management of OHSS is awaited with interest.</description><subject>Adult</subject><subject>Ascitic Fluid - chemistry</subject><subject>Biological and medical sciences</subject><subject>Cytokines</subject><subject>Endothelial Growth Factors - analysis</subject><subject>Endothelial Growth Factors - blood</subject><subject>Female</subject><subject>Female genital diseases</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>IL-2</subject><subject>IL-6</subject><subject>Interleukin-2 - analysis</subject><subject>Interleukin-2 - blood</subject><subject>Interleukin-6 - analysis</subject><subject>Interleukin-6 - blood</subject><subject>Lymphokines - analysis</subject><subject>Lymphokines - blood</subject><subject>Medical sciences</subject><subject>Non tumoral diseases</subject><subject>OHSS</subject><subject>Ovarian Hyperstimulation Syndrome - blood</subject><subject>Ovarian Hyperstimulation Syndrome - metabolism</subject><subject>Receptors, Interleukin-2 - analysis</subject><subject>Receptors, Interleukin-2 - blood</subject><subject>Receptors, Interleukin-6 - analysis</subject><subject>Receptors, Interleukin-6 - blood</subject><subject>Reference Values</subject><subject>Solubility</subject><subject>Vascular Endothelial Growth Factor A</subject><subject>Vascular Endothelial Growth Factors</subject><subject>VEGF</subject><issn>0301-2115</issn><issn>1872-7654</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkd9qFDEUxoModlt9BCUXIgodTWYmmclVkVL_QMEL9TpkkzNuNJOMSWbLPrZv0Mzuoi0I3uRAzu875-N8CD2j5A0llL_9QhpCq5pS9kqI14SQvq7qB2hF-66uOs7ah2j1BzlBpyn9KBBpGvEYnVDCOsFrukK_rxxsVQaDSwWXcBiw9Rmig_mn9VV9jlNw89rB_W8cQcOUQ8TKTRt1fq_L_y3id0Te4K1KenYqYvAm5A04qxz-HsNN3uBB6QWzHieI87jnC26z1XhwszWLz0llCz4nfGOLJBX_EXDYqmiVx5vdBDFlO5YV2YYyaOdNDCM8QY8G5RI8PdYz9O391dfLj9X15w-fLt9dV7qlIleKKEEIY-VpVN8aBoT2GlqlCAFqesPXTOuuIaRlLWlrXnp9J5per4G1TdecoZeHuVMMv2ZIWY42aXBOeQhzklw0Ne37BWQHUMeQUoRBTtGOKu4kJXLJWu6zlkuQUgi5z1rWRff8uGBej2DuqA7hFuDFESinU26Iymub_nKCC04X7OKAlfhhayHKcmjwGowteWVpgv2Pk1vVP8wY</recordid><startdate>19991101</startdate><enddate>19991101</enddate><creator>Aboulghar, M.A.</creator><creator>Mansour, R.T.</creator><creator>Serour, G.I.</creator><creator>El Helw, B.A.</creator><creator>Shaarawy, M.</creator><general>Elsevier Ireland Ltd</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19991101</creationdate><title>Elevated levels of interleukin-2, soluble interleukin-2 receptor alpha, interleukin-6, soluble interleukin-6 receptor and vascular endothelial growth factor in serum and ascitic fluid of patients with severe ovarian hyperstimulation syndrome</title><author>Aboulghar, M.A. ; Mansour, R.T. ; Serour, G.I. ; El Helw, B.A. ; Shaarawy, M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c419t-a0a900559003a84d5e018ce4aa00e1d8d6b5cc73004540426ce487938cbe54373</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Adult</topic><topic>Ascitic Fluid - chemistry</topic><topic>Biological and medical sciences</topic><topic>Cytokines</topic><topic>Endothelial Growth Factors - analysis</topic><topic>Endothelial Growth Factors - blood</topic><topic>Female</topic><topic>Female genital diseases</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>IL-2</topic><topic>IL-6</topic><topic>Interleukin-2 - analysis</topic><topic>Interleukin-2 - blood</topic><topic>Interleukin-6 - analysis</topic><topic>Interleukin-6 - blood</topic><topic>Lymphokines - analysis</topic><topic>Lymphokines - blood</topic><topic>Medical sciences</topic><topic>Non tumoral diseases</topic><topic>OHSS</topic><topic>Ovarian Hyperstimulation Syndrome - blood</topic><topic>Ovarian Hyperstimulation Syndrome - metabolism</topic><topic>Receptors, Interleukin-2 - analysis</topic><topic>Receptors, Interleukin-2 - blood</topic><topic>Receptors, Interleukin-6 - analysis</topic><topic>Receptors, Interleukin-6 - blood</topic><topic>Reference Values</topic><topic>Solubility</topic><topic>Vascular Endothelial Growth Factor A</topic><topic>Vascular Endothelial Growth Factors</topic><topic>VEGF</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Aboulghar, M.A.</creatorcontrib><creatorcontrib>Mansour, R.T.</creatorcontrib><creatorcontrib>Serour, G.I.</creatorcontrib><creatorcontrib>El Helw, B.A.</creatorcontrib><creatorcontrib>Shaarawy, M.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of obstetrics & gynecology and reproductive biology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Aboulghar, M.A.</au><au>Mansour, R.T.</au><au>Serour, G.I.</au><au>El Helw, B.A.</au><au>Shaarawy, M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Elevated levels of interleukin-2, soluble interleukin-2 receptor alpha, interleukin-6, soluble interleukin-6 receptor and vascular endothelial growth factor in serum and ascitic fluid of patients with severe ovarian hyperstimulation syndrome</atitle><jtitle>European journal of obstetrics & gynecology and reproductive biology</jtitle><addtitle>Eur J Obstet Gynecol Reprod Biol</addtitle><date>1999-11-01</date><risdate>1999</risdate><volume>87</volume><issue>1</issue><spage>81</spage><epage>85</epage><pages>81-85</pages><issn>0301-2115</issn><eissn>1872-7654</eissn><coden>EOGRAL</coden><abstract>Objective: To investigate the possible role of vascular endothelial growth factor, interleukin-2, soluble interleukin-2 receptor alpha, interleukin-6 and soluble interleukin-6 receptor in the pathogenesis of ovarian hyperstimulation syndrome.
Study design: The study group consisted of 10 healthy women who developed severe ovarian hyperstimulation syndrome, group A (
n=10), following ovarian stimulation by long GnRHa/hMG protocol for IVF. A control group B=10 patients underwent stimulation with the same protocol and did not develop OHSS. Blood and ascitic fluid samples were assayed for VEGF, IL-2, sIL-2Rα, IL-6 and sIL-6R by ELISA.
Results: The mean serum levels of IL-2, sIL-2Rα, IL-6, sIL-6R and VEGF in OHSS group were 297.5±190, 6588±5566, 40.6±16.6, 5280±3326 and 492±165 pg/ml as compared to 50.8±17.4, 1100±391.6, 8.5±3.5, 516±342 and 167±31.3 pg/ml in the control group, respectively,
P<0.001. The mean ascitic fluid IL-2, sIL-2Rα, IL-6, sIL-6R and VEGF in the OHSS group were 282.5±191.5 pg/ml, 26 020±13 995, 90.5±36, 14 900±2789 and 660±359 pg/ml as compared to 32±14.8, 1206±429.4, 12.6±1.7, 614±240 and 151±20.5 pg/ml, respectively,
P<0.001.
Conclusions: The significantly high levels of VEGF in patients with severe OHSS suggest that VEGF is a major capillary permeability agent in OHSS. Elevated levels of IL-6 in serum and peritoneal fluid support the hypothesis that IL-6 may serve as a marker of OHSS. Although serum and ascitic fluid levels of IL-2 were elevated, accumulating evidence does not support a pivotal role for IL-2 in the pathogenesis of OHSS. However, it may have a peripheral role in mediating an increase in vascular permeability. Soluble IL-2Rα and sIL-6R may be considered to be involved in OHSS. However, the patho-physiologic mechanism is the subject of further investigations. Clinical application of VEGF-receptors in the management of OHSS is awaited with interest.</abstract><cop>Shannon</cop><pub>Elsevier Ireland Ltd</pub><pmid>10579621</pmid><doi>10.1016/S0301-2115(99)00082-2</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0301-2115 |
| ispartof | European journal of obstetrics & gynecology and reproductive biology, 1999-11, Vol.87 (1), p.81-85 |
| issn | 0301-2115 1872-7654 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_69321887 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | Adult Ascitic Fluid - chemistry Biological and medical sciences Cytokines Endothelial Growth Factors - analysis Endothelial Growth Factors - blood Female Female genital diseases Gynecology. Andrology. Obstetrics Humans IL-2 IL-6 Interleukin-2 - analysis Interleukin-2 - blood Interleukin-6 - analysis Interleukin-6 - blood Lymphokines - analysis Lymphokines - blood Medical sciences Non tumoral diseases OHSS Ovarian Hyperstimulation Syndrome - blood Ovarian Hyperstimulation Syndrome - metabolism Receptors, Interleukin-2 - analysis Receptors, Interleukin-2 - blood Receptors, Interleukin-6 - analysis Receptors, Interleukin-6 - blood Reference Values Solubility Vascular Endothelial Growth Factor A Vascular Endothelial Growth Factors VEGF |
| title | Elevated levels of interleukin-2, soluble interleukin-2 receptor alpha, interleukin-6, soluble interleukin-6 receptor and vascular endothelial growth factor in serum and ascitic fluid of patients with severe ovarian hyperstimulation syndrome |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T07%3A55%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Elevated%20levels%20of%20interleukin-2,%20soluble%20interleukin-2%20receptor%20alpha,%20interleukin-6,%20soluble%20interleukin-6%20receptor%20and%20vascular%20endothelial%20growth%20factor%20in%20serum%20and%20ascitic%20fluid%20of%20patients%20with%20severe%20ovarian%20hyperstimulation%20syndrome&rft.jtitle=European%20journal%20of%20obstetrics%20&%20gynecology%20and%20reproductive%20biology&rft.au=Aboulghar,%20M.A.&rft.date=1999-11-01&rft.volume=87&rft.issue=1&rft.spage=81&rft.epage=85&rft.pages=81-85&rft.issn=0301-2115&rft.eissn=1872-7654&rft.coden=EOGRAL&rft_id=info:doi/10.1016/S0301-2115(99)00082-2&rft_dat=%3Cproquest_cross%3E69321887%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=69321887&rft_id=info:pmid/10579621&rft_els_id=S0301211599000822&rfr_iscdi=true |